Icovamenib boosts C-peptide secretion in 52-week diabetes trial

Icovamenib boosts C-peptide secretion in 52-week diabetes trial
Biomea Fusion trial boosts C-peptide

Biomea Fusion reported that the recently released 52-week results from its Phase II COVALENT-112 trial evaluating icovamenib in type 2 diabetes revealed increased C-peptide secretion.

Dr. G. Alexander Zan Fleming, MD, a former FDA senior medical officer and a recognized leader in diabetes drug development, presented these findings, indicating a potentially significant advance in diabetes treatment research. The focus on C-peptide secretion highlights the trial's emphasis on pancreatic beta-cell function, a crucial marker for therapeutic efficacy in diabetes management.

Biomea Fusion previously reported that diabetes remains poorly controlled in many patients, pointing to ongoing unmet needs in current therapies (read more). The company also recently launched enrollment for its COVALENT-212 clinical trial evaluating icovamenib in type 2 diabetes patients (read more). These efforts reflect Biomea Fusion’s continuing focus on advancing diabetes treatment options.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.